Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 420

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993)

Open access
Marks, David I., Paietta, Elisabeth M., Moorman, Anthony V., Richards, Susan M., Buck, Georgina, DeWald, Gordon, Ferrando, Adolfo, Fielding, Adele K., Goldstone, Anthony H., Ketterling, Rhett P., Litzow, Mark R., Luger, Selina M., McMillan, Andrew K., Mansour, Marc R., Rowe, Jacob M., Tallman, Martin S., Lazarus, Hillard M.·2009·Blood

Abstract

The biology and outcome of adult T-cell acute lymphoblastic leukemia are poorly understood. We present here the clinical and biologic features of 356 patients treated uniformly on the prospective trial (UKALL XII/ECOG 2993) with the aim of describing the outcome and identifying prognostic factors. Complete remission was obtained in 94% of patients, and 48% survived 5 years. Positivity of blasts for CD1a and lack of expression of CD13 were associated with better survival (P = .01 and < .001, respectively). NOTCH1 and CDKN2A mutations were seen in 61% and 42% of those tested. Complex cytogenetic abnormalities were associated with poorer survival (19% vs 51% at 5 years, P = .006). Central nervous system involvement at diagnosis did not affect survival (47% vs 48%, P = not significant). For 99 patients randomized between autograft and chemotherapy, 5-year survival was 51% in each arm. Patients with a matched sibling donor had superior 5-year survival to those without donors (61% vs 46%, χ2, P = .02); this was the result of less relapse (25% vs 51% at 5 years, P < .001). Only 8 of 123 relapsed patients survive. This study provides a baseline for trials of new drugs, such as nelarabine, and may allow risk-adapted therapy in patients with poor-prognosis T-cell ALL.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2009-08-231217

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 420

Metadata

Authors
Marks, D. I., Paietta, E. M., Moorman, A. V., Richards, S. M., Buck, G., DeWald, G., Ferrando, A., Fielding, A. K., Goldstone, A. H., Ketterling, R. P., Litzow, M. R., Luger, S. M., McMillan, A. K., Mansour, M. R., Rowe, J. M., Tallman, M. S., & Lazarus, H. M.
Venue
Blood
Published
2009-12-10
Volume
114
Issue
25
Pages
5136-5145
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W2085453248
Cited by
420
References
1
FWCI
18.22
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993). https://app.cochat.ai/papers/10.1182/blood-2009-08-231217
The paper
Marks, D. I., Paietta, E. M., Moorman, A. V., Richards, S. M., Buck, G., DeWald, G., Ferrando, A., Fielding, A. K., Goldstone, A. H., Ketterling, R. P., Litzow, M. R., Luger, S. M., McMillan, A. K., Mansour, M. R., Rowe, J. M., Tallman, M. S., & Lazarus, H. M. (2009). T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993). Blood. https://doi.org/10.1182/blood-2009-08-231217

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.